CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
about
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaRegulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingNovel technologies and emerging biomarkers for personalized cancer immunotherapyHomeostasis and function of regulatory T cells (Tregs) in vivo: lessons from TCR-transgenic TregsTherapeutic cancer vaccines: past, present, and futureThe role of regulatory T cells in cancer immunologySynergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 BlockadeIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsModification of the tumor microenvironment as a novel target of renal cell carcinoma therapeuticsAn African ancestry-specific allele of CTLA4 confers protection against rheumatoid arthritis in African Americans.Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyCTLA4 blockade broadens the peripheral T-cell receptor repertoireAntibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Ipilimumab augments antitumor activity of bispecific antibody-armed T cellsImmuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis.CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cellsCurrent status of interleukin-10 and regulatory T-cells in cancerOX40 is a potent immune-stimulating target in late-stage cancer patients.T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadePrimary mucosal melanoma arising from the eustachian tube with CTLA-4, IL-17A, IL-17C, and IL-17E upregulationT cell pathways involving CTLA4 contribute to a model of acute lung injury.TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccinationHigher proportions of circulating FOXP3+ and CTLA-4+ regulatory T cells are associated with lower fractions of memory CD4+ T cells in infants.Prostate cancer immunotherapy.Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.Immunotherapy for melanoma: current status and perspectives.Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.Enhanced selection of FoxP3+ T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease.CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
P2860
Q24629841-327F76A2-FA70-4E9E-9D8E-500FB0EA3236Q26742012-AE37B79C-DE3C-42DE-A4BE-18267089676AQ26770780-172584A2-F399-478C-B2B2-5D0601C91FCDQ26853599-105F343E-89B7-4F3E-B6D8-89C4646B696DQ26863283-928C6D7E-4329-45BE-8173-3CAFF486643FQ27006663-AD596EC9-B757-4DB5-B8D2-4DE9A3737AE7Q27487939-2E92EEC0-809D-4A61-B8C0-DFB970083C61Q28072532-68B964E6-AE03-4010-807E-DA74A9DB9FC8Q28393614-810148A2-21EA-4C51-9A65-BE71A8AFB2C2Q33419824-AC2B2730-61CA-4046-9226-F88A2FC75B11Q33522281-F44F0460-7B24-4FC2-8211-C51E96FACE0AQ33560753-7D7637BB-50FD-47FB-A467-9AD48113B8D0Q33699687-8583E1CA-20D0-4C8A-8367-09F3758D2A05Q33929184-393854C4-DAFD-4DAC-83C7-8D43096CCDF9Q33968361-495BB94C-CF41-44C4-884F-F4E85C4DD3A7Q34048386-06CEFF29-5158-4DBE-9FDC-F190E08B172BQ34355686-4E342FD7-0397-4881-8D4C-0F24A743B0BFQ34374026-D0D64965-915B-4749-82EA-5F5EEAECEE6FQ34381674-4074BA9C-2D46-4654-A188-F46586BDAB8EQ34577158-32535605-5819-4FCF-A011-1C232D2AAFC4Q34645401-B2628620-D491-4FBA-9A57-81E5D9BBD486Q34647661-552FDBE2-23C0-4D08-96C2-0571B28BAFE8Q34748704-869434E7-605E-455E-919A-41BCAF09150BQ34880391-FD9ECC9B-01C6-4060-AA63-3F91C6088592Q34898280-9F944416-3F1E-4E0C-BC29-B3FE617E7CC0Q35053486-E77C28DE-8FCD-4F49-96B7-FD5F157B2444Q35451153-210A38AE-1A2D-439B-8239-71C43F3DFC9DQ35609361-A48CE23B-7F56-4307-B2D3-41FDD037CCBEQ35688425-9262A2CB-F5F5-4C6B-9C74-913EA5B916E6Q36011105-7960DDD4-C93C-4026-B239-1800C36BC330Q36020800-3C00ABE6-43DD-4DE1-B229-E1AFC2E8D6AFQ36031597-7EF002B7-AEE7-4A52-ACB6-3A9807FC53C3Q36293343-C365DD5E-8446-4AC2-90F5-BDB5A3F28319Q36443331-604622C7-F9B2-4137-AD74-2CE11E8DEF34Q36453216-D66C9150-DEAA-4DE1-86BF-432091B7A829Q36884975-93BF4F4A-FBCB-48C6-BE07-AE53C79E9515Q37017085-FF3B3857-B0E5-4447-9101-DF1380072FC7Q37024260-57DDB629-7298-443F-AED9-D926F503A48DQ37097201-CD2E8CA2-93F2-4637-9657-D7FE1ECEE73CQ37229358-2991AB55-87EC-43B0-81B6-F932D93550C7
P2860
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
CTLA4 blockade expands FoxP3+ ...... ls in a dose-dependent fashion
@en
type
label
CTLA4 blockade expands FoxP3+ ...... ls in a dose-dependent fashion
@en
prefLabel
CTLA4 blockade expands FoxP3+ ...... ls in a dose-dependent fashion
@en
P2093
P2860
P1433
P1476
CTLA4 blockade expands FoxP3+ ...... ls in a dose-dependent fashion
@en
P2093
Brian Kavanagh
Brian Rini
Eric J Small
Lawrence Fong
Shaun O'Brien
Vivian Weinberg
P2860
P304
P356
10.1182/BLOOD-2007-11-125435
P407
P577
2008-06-03T00:00:00Z